Shots: The initiation of the post-exposure prophylaxis clinical trial follows Korean MFDS’ IND approval on Oct 08, 2020 The study will assess the preventive effect & safety of CT-P59 in […]readmore
Tags : mAb
Shots: The approval is based on P-III EORTC1325/KEYNOTE-054 trial assessing Keytruda (IV 200mg, q3w) as adjuvant therapy vs PBO, in 1,019 patients in ratio (1:1) with completely resected melanoma (stage IIIA [>1 mm […]readmore
Biosimilars
Biotech
Celltrion’s Truxima (rituximab-abbs) Receives FDA’s Approval for Three on-Hodgkin’s Lymphoma
Shots: The approval is based on non-inferiority data demonstrating biosimilarity in pharmacology, immunogenicity, clinical efficacy with safety, potency and purity when compared to reference medicine (rituxan) Truxima is a mAb, […]readmore
Shots: The P-III MYSTIC Trial involves assessing of Imfinzi (durvalumab) as a monothx or Imfinzi plus tremelimumab vs SoC Pt-based CT in patients with EGFR and anaplastic lymphoma kinase (ALK) […]readmore